The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
Chadban
S
S
Howell
M
M
Twigg
S
S
Thomas
M
M
Jerums
G
G
Cass
A
A
Campbell
D
D
Nicholls
K
K
Tong
A
A
Mangos
G
G
Stack
A
A
MacIsaac
R J
RJ
Girgis
S
S
Colagiuri
R
R
Colagiuri
S
S
Craig
J
J
D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control* / Q000628:therapy; D012923:Social Class
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors